Moxifloxacin is a member of the fluoroquinolones class of antibacterial agents. It has a broad spectrum of activity and antibacterial action. It exerts activity against a wide range of Gram-positive, Gram-negative, anaerobic, and atypical bacteria, including Mycoplasma pneumoniae. The bactericidal action results from the inhibition of topoisomerase II (DNA gyrase) and topoisomerase IV, which are required for bacterial DNA replication, transcription, and repair.
Zydus® is indicated for the treatment of the following infections caused by susceptible bacteria:
Acute Bacterial Sinusitis
Acute Bacterial Exacerbation of Chronic Bronchitis
Community Acquired Pneumonia
Uncomplicated Skin and Skin Structure Infections
Complicated Skin and Skin Structure Infections
Complicated Intra-Abdominal Infections
The recommended dose of Zydus is 400 mg once daily. The duration of therapy depends on the type of infection, as described in the following table.
No dosage adjustment is required in patients with renal or hepatic impairment.
Zydus® is contraindicated in patients with known hypersensitivity to Moxifloxacin or other quinolones.
Most side effects reported with Moxifloxacin treatment are mild to moderate in nature and require no treatment. The most common adverse reactions are nausea, diarrhea, and dizziness.
Pregnancy: Pregnancy Category C. Since no adequate or well-controlled studies have been conducted in pregnant women, Moxifloxacin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Nursing Mothers: Moxifloxacin may be excreted in human breast milk. Because of the potential for serious adverse reactions in infants, nursing mothers taking Moxifloxacin should decide whether to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother.
Pediatric Patients: Safety and effectiveness in pediatric patients and adolescents less than 18 years of age have not been established.
Moxifloxacin has been shown to prolong the QT interval in some patients, and it should be avoided in these cases. It should also be avoided in patients with known QT prolongation, hypokalemia, or those taking drugs that prolong the QT interval. Moxifloxacin may increase the risk of tendinitis and tendon rupture. If pain or inflammation in a tendon occurs, the drug should be discontinued immediately.
Antacids, sucralfate, multivitamins, and other products containing multivalent cations: These can reduce the absorption of Moxifloxacin. It should be administered 4 hours before or 8 hours after antacids, sucralfate, multivitamins, and other products containing multivalent cations.
Warfarin: Moxifloxacin may enhance the anticoagulant effect of warfarin.
Class IA and Class III antiarrhythmics: Moxifloxacin may enhance the proarrhythmic effect of these drugs. Therefore, concomitant use should be avoided.
No clinically significant drug interactions with theophylline, digoxin, or glyburide have been observed with Moxifloxacin.
Store at a temperature not exceeding 30°C in a dry place. Protect from light and moisture.
Medicine: Keep out of reach of children.
